

GUIDELINE

Open Access



A time-efficient protocol for transthoracic echocardiography during transfemoral transcatheter aortic valve implantation: early identification and effective management of intraprocedural complications

Panagiotis Savvoulidis¹, William E. Moody^{1,2}, Rick Steeds^{1,2}, Peter F. Ludman^{1,2}, Joseph R. Bradley¹, Aldrin Singh¹, Ewa Lawton¹, M. Adnan Nadir^{1,2} and Sagar N. Doshi^{1,2*}

Abstract

Transfemoral transcatheter aortic valve implantation (TAVI) under conscious sedation is the most widely used method of implantation. Echocardiography is used to detect complications and to assess the implantation result. The aim of this paper is to provide a time-efficient protocol when transthoracic echocardiography (TTE) is used to guide TAVI procedures.

Keywords: Transcatheter aortic valve implantation, Echocardiography guidance, Complications

Introduction

Transfemoral transcatheter aortic valve implantation (TAVI) undertaken with conscious sedation, rather than with general anaesthesia, is the most widely practised mode of implantation in Europe. Transthoracic echocardiography (TTE) is the main form of imaging employed in these procedures and is used to detect complications, assess the result of transcatheter heart valve (THV) implantation and guide further management. We propose a time-efficient, focused protocol for echocardiographers to follow when echocardiography is used to guide transfemoral TAVI undertaken with conscious sedation. This protocol provides guidance on which key assessments are required, important pitfalls and provides examples of important complications that may arise in

order to allow timely identification and effective management. In the modern era of minimalist TAVI with transfemoral access and conscious sedation, transoesophageal echocardiography (TOE) may be preferable in a small proportion of TAVI procedures undertaken with general anaesthesia, with the benefit of continuous echocardiographic monitoring and reduced risk of contamination of the sterile field. TOE guidance may also be preferable in patients with severe renal insufficiency, particularly in conjunction with fusion imaging, to minimize contrast use and the consequent risk of renal injury.

Background

Aortic stenosis is the most prevalent valvular lesion in Europe and North America [1, 2]. The first Transcatheter Aortic Valve Implantation (TAVI) procedure was performed in man in 2002 [3] and transcatheter heart valves (THV) became commercially available in Europe in 2007 and in North America in 2011. TAVI has become the treatment of choice in patients considered inoperable and

*Correspondence: Sagar.Doshi@uhb.nhs.uk

¹ Department of Cardiology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2WB, UK
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

at high operative risk and is increasingly used in patients at intermediate and low risk, supported by guidelines[4, 5]. In the early years of TAVI, due to the large profile of the delivery catheters employed, particularly with balloon-expandable technologies, procedures were undertaken with general anaesthesia with surgical cut down for femoral access. Intraprocedural transoesophageal echocardiographic guidance was the norm[6, 7]. However, TOE carries a risk of oesophageal injury and increases procedure times[8, 9]. Since 2007 there has been serial reduction in the entry profile of delivery devices for THVs such that a greater proportion of patients are suitable for transfemoral procedures. Over 90% of cases in the UK are now undertaken with percutaneous, transfemoral access under conscious sedation. This shift in practice from general anaesthesia to conscious sedation has been accompanied by a transition from TOE to TTE as the intraprocedural imaging modality of choice.

Role of intraprocedural TTE

Intraprocedural echocardiographic imaging is used principally to assess prosthetic valve function post-deployment and to allow early detection of complications. There are 3 distinct phases where TTE is employed in TAVI procedures:

1. On-table pre-procedure assessment
2. Immediate post THV deployment assessment
3. Pre-cath lab exit assessment

On-table pre-procedure assessment

A rapid assessment should be made whilst preparations are underway for gaining vascular access. The value of this is to allow a baseline study for comparison with changes that may develop during the procedure. The location of optimal echocardiographic windows should be carefully noted in order to improve quality and avoid suboptimal images which may delay the procedure and hamper accurate assessment. Where necessary, slight tilting of the patient with a wedge under the right chest may be employed to improve echocardiographic image quality. Careful positioning at the start of the procedure

is important as the patient may be unable to move and reposition themselves during the procedure. Additionally, image acquisition should be done with ECG-triggering as standard (Fig. 1A). This ensures measurements are taken during the correct phase of the cardiac cycle. This is particularly important when documenting the size of pericardial effusion, which should be assessed at end-diastole (Fig. 1A) or LVOT diameter measurement, which should be taken at mid-systole. To ensure standardization of measurements, it is recommended that the Nyquist limit should be set between 50 and 60 cm/s and where appropriate by reducing colour flow Doppler region of interest in order that colour flow frame rates are kept above 20/s. An evaluation of the pericardial space is particularly important. Presence of pre-existing pericardial effusion (Fig. 1A) and epicardial fat (Fig. 1B) that may subsequently be confused for a new pericardial effusion should be noted. Views should be obtained from the subcostal, left-parasternal and apical windows. An assessment should also be made of left ventricular function and the presence and severity of mitral regurgitation should also be noted. An in-depth assessment of these parameters is not required as the principal purpose of the examination is to allow rapid identification of changes. The entire assessment should take less than 5 min to complete.

Immediate post THV deployment assessment

Immediately post THV deployment echocardiography should be undertaken to rapidly identify complications, to assess prosthesis function and paravalvular regurgitation.

Pericardial effusion

The first imaging window is the subcostal region to assess for development of pericardial effusion which may indicate injury to the annular complex or LVOT (1C Right). A comparison with the immediate pre-procedure images is important to help determine new changes (1C Left, Additional file 1: Video S1). Pericardial effusion noted on echo is often visible before haemodynamic changes develop. If new pericardial effusion or a change in size of a pre-existing effusion is noted, careful attention should

(See figure on next page.)

Fig. 1 **A** Baseline echocardiogram showing small < 1 cm pericardial effusion (arrow). **B** A pericardial fat pad was noted on the baseline echocardiogram (arrow). This may be confused with a pericardial effusion on the post-deployment study. **C** A small pericardial effusion (arrow) was noted on the baseline study (Left). Post THV deployment the effusion enlarged (arrow) and required emergency pericardiocentesis (Right). **D** Long axis view showing wire-induced AR (arrow). The colour Doppler jet often 'hugs' the wire (Right). On the short axis view the wire-induced AR lies within the frame (Left) and is adjacent to the stiff wire (arrow). **E** On short axis a moderate jet of PVR can be seen at 3 o'clock with trivial jets at 10–12 o'clock. The jets lie outside the THV frame (Left). Apical 5 chamber view showing the PVR jet (arrow) outside the frame (Right). **F** A interventricular VSD was noted after deployment of a balloon expandable THV. The VSD was visible on the short axis (left) and long axis (right)




Fig. 1 (See legend on previous page.)

be given to haemodynamic indicators of tamponade and the effusion should be carefully monitored over several minutes. If a growing pericardial effusion is noted equipment should be readied for emergency pericardiocentesis and aortography undertaken to detect a bleeding source. The surgical team may need to be alerted to consider the need for emergency sternotomy.

Aortic regurgitation

Both paravalvular (PVR) and transvalvular aortic regurgitation (TAR) may be seen post THV deployment. Assessment should be made from short axis, left parasternal long axis and apical windows. TAR may be artefactually caused by the stiff catheter delivery wire. A transverse, short-axis view just below the THV in the LVOT is particularly useful in differentiating wire-induced TAR from PVR (Additional file 2: Video S2). Wire-induced TAR will be seen 'hugging' and adjacent to the wire (Fig. 1D Right). The left parasternal long axis view and apical three and five chamber views are also useful and turbulent flow on colour Doppler may be identified around the wire (Fig. 1D Left, Additional file 3: Video S3).

PVR arises from outside the THV frame and is best identified on the short axis LVOT view, just below the THV (Fig. 1E Left, Additional file 4: Video S4) and may also be seen on the parasternal long axis, apical three and five chamber views (Fig. 1E Right, Additional file 5: Video S5). Moderate or severe, but not mild or trivial, PVR is associated with increased 1 year mortality after TAVI [10, 11]. Identification of moderate or severe PVR may guide further balloon valvuloplasty to reduce paravalvular regurgitation with both balloon-expandable and self-expanding valves.

Ventricular function

Coronary obstruction may complicate THV deployment and is seen in approximately 1% of cases. The left main coronary artery is most often involved and females are affected more commonly [12]. The resulting ischaemia may cause global or regional wall motion abnormalities, which are usually associated with evidence of ischaemia on the ECG and hypotension. If new global or regional left ventricular dysfunction is seen a root aortogram or selective coronary angiogram should be immediately undertaken.

Ventricular septal defects

A rare complication of TAVI is iatrogenic ventricular septal defect with an incidence of <0.4% [13].

Interventricular defects are most common (Fig. 1F, Additional file 6: Video S6, Additional file 7: Video S7) with LV-RA defects being rarer. They are thought to arise as a result of focal annular rupture [14]. They may be asymptomatic or cause heart failure. Small and asymptomatic defects may be managed conservatively but larger defects may warrant surgical or percutaneous closure.

Damage to mitral valve apparatus

Damage to sub-valvular mitral apparatus may result in mitral regurgitation and a comparison with the pre-procedure images is important to determine whether mitral regurgitation is new or pre-existing. Sub-valvular apparatus damage can occur when the guide wire inadvertently passes through the mitral valve apparatus leading to subsequent damage of the chordae by the valve or injudicious wire removal.


Entanglement of the stiff guide wire can be assessed with TOE, however, the fluoroscopic appearances and movement of the guide wire have largely superseded echocardiographic identification of entanglement with the sub valvular mitral apparatus.

Post procedure pre lab-exit echocardiogram

A focused echocardiogram should be undertaken before leaving the catheterization laboratory. Repeat assessment is undertaken to ensure that no pericardial effusion has developed since the immediate post THV deployment study. Assessment is made of the aortic valve and parameters are gained for measurement of aortic valve area, peak and mean gradient and a final assessment of aortic and mitral regurgitation and LV function. This obviates the need for a further routine TTE on the ward in the absence of a clinical change, thereby reducing costs and the burden on echocardiography services.

Conclusion

With the continued growth of TAVI undertaken with conscious sedation rather than general anaesthesia, TTE has become the dominant periprocedural echocardiographic modality [15]. Echocardiographers should exercise a time-efficient protocol involving on-table baseline assessment, immediate post-deployment assessment and a final pre-lab exit study (Fig. 2). Early recognition of periprocedural complications using echocardiography permits timely intervention and may improve outcomes.



Abbreviations

TAVI: Transcatheter aortic valve implantation; TOE: Transoesophageal echocardiography; THV: Transcatheter heart valve; TTE: Transthoracic echocardiography.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s44156-022-00005-6>.

Additional file 1: Video S1: Subcostal view post THV deployment showing a new pericardial effusion with RV invagination.

Additional file 2: Video S2: Short axis view showing trans valvular aortic regurgitation (12 o'clock). Jet lies within the THV frame and adjacent to the delivery wire.

Additional file 3: Video S3: Apical 5 chamber view showing TAR jet within the THV frame and 'hugging' the delivery wire.

Additional file 4: Video S4: Small PVR jets at 12 o'clock. Larger PVR jet at 3 o'clock. PVR lies outside the THV frame.

Additional file 5: Video S5: Apical 5 chamber view showing PVR jet outside the THV.

Additional file 6: Video S6: Parasternal long axis view showing small VSD post deployment of balloon expandable THV.

Additional file 7: Video S7: Short axis view at LVOT level showing VSD.

Acknowledgements

Not applicable.

Authors' contributions

All authors contributed equally in the writing and editing of the manuscript. All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript in accordance with ICMJE criteria. All authors read and approved the final manuscript.

Funding

There is no funding.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Consent has been granted from participants for free availability of anonymized images/videos on the internet and may be seen by the general public.

Competing interests

Dr SN Doshi is a proctor for Edwards LifeSciences and has received speaker fees from Medtronic and Boston Scientific. The other authors have no disclosures.

Author details

¹Department of Cardiology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2WB, UK. ²Institute for Cardiovascular Sciences, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Received: 23 February 2022 Accepted: 28 May 2022

Published online: 17 August 2022

References

1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. *Eur Heart J*. 2003;24(13):1231–43.
2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *The Lancet*. 2006;368(9540):1005–11.
3. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. *Circulation*. 2002;106(24):3006–8.
4. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;143(5):e72–227.
5. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2021. <https://doi.org/10.1093/eurheartj/ehab395>.
6. Demarco DC, Monaghan MJ. The role of echocardiography in transcatheter aortic valve implantation. *Interv Cardiol*. 2014;6:547–56.
7. Zamorano JL, Badano LP, Bruce C, Chan K-L, Gonçalves A, Hahn RT, et al. EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. *Eur Heart J*. 2011;32(17):2189–214.

8. Freitas-Ferraz AB, Bernier M, Vaillancourt R, Ugalde PA, Nicodeme F, Paradis JM, et al. Safety of transesophageal echocardiography to guide structural cardiac interventions. *J Am Coll Cardiol*. 2020;75(25):3164–73.
9. Ramalingam G, Choi SW, Agarwal S, Kunst G, Gill R, Fletcher SN, et al. Complications related to peri-operative transoesophageal echocardiography—a one-year prospective national audit by the Association of Cardiothoracic Anaesthesia and Critical Care. *Anaesthesia*. 2020;75(1):21–6.
10. Herrmann HC, Thourani VH, Kodali SK, Makkar RR, Szeto WY, Anwaruddin S, et al. One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis. *Circulation*. 2016;134(2):130–40.
11. Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. *Eur Heart J*. 2015;36(7):449–56.
12. Ribeiro HB, Nombela-Franco L, Urena M, Mok M, Pasian S, Doyle D, et al. Coronary obstruction following transcatheter aortic valve implantation: a systematic review. *JACC Cardiovasc Interv*. 2013;6(5):452–61.
13. Nona P, Mahmood S, Lemor A, Qintar M, O'Neill B, Lee J, et al. Incidence of acquired ventricular septal defect after transcatheter aortic valve replacement: a large single center experience. *Catheter Cardiovasc Interv*. 2021;98(5):975–80.
14. Ando T, Holmes AA, Taub CC, Slovut DP, DeRose JJ. Iatrogenic ventricular septal defect following transcatheter aortic valve replacement: a systematic review. *Heart Lung Circ*. 2016;25(10):968–74.
15. Kronzon I, Jelnin V, Ruiz CE, Saric M, Williams MR, Kasel AM, et al. Optimal imaging for guiding TAVR: transesophageal or transthoracic echocardiography, or just fluoroscopy? *JACC Cardiovasc Imaging*. 2015;8(3):361–70.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

